Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson’s patients
-
Published:2024-06-05
Issue:7
Volume:16
Page:1657-1674
-
ISSN:1757-4684
-
Container-title:EMBO Molecular Medicine
-
language:en
-
Short-container-title:EMBO Mol Med
Author:
de Boni LauraORCID, Wallis Amber, Hays Watson Aurelia, Ruiz-Riquelme AlejandroORCID, Leyland Louise-Ann, Bourinaris Thomas, Hannaway Naomi, Wüllner Ullrich, Peters Oliver, Priller JosefORCID, Falkenburger Björn H, Wiltfang JensORCID, Bähr Mathias, Zerr Inga, Bürger Katharina, Perneczky RobertORCID, Teipel Stefan, Löhle Matthias, Hermann Wiebke, Schott Björn-HendrikORCID, Brockmann Kathrin, Spottke Annika, Haustein Katrin, Breuer Peter, Houlden Henry, Weil Rimona SORCID, Bartels TimORCID
Abstract
AbstractSynucleinopathies such as Parkinson’s disease (PD) are defined by the accumulation and aggregation of the α-synuclein protein in neurons, glia and other tissues. We have previously shown that destabilization of α-synuclein tetramers is associated with familial PD due to SNCA mutations and demonstrated brain-region specific alterations of α-synuclein multimers in sporadic PD patients following the classical Braak spreading theory. In this study, we assessed relative levels of disordered and higher-ordered multimeric forms of cytosolic α-synuclein in blood from familial PD with G51D mutations and sporadic PD patients. We used an adapted in vitro-cross-linking protocol for human EDTA-whole blood. The relative levels of higher-ordered α-synuclein tetramers were diminished in blood from familial PD and sporadic PD patients compared to controls. Interestingly, the relative amount of α-synuclein tetramers was already decreased in asymptomatic G51D carriers, supporting the hypothesis that α-synuclein multimer destabilization precedes the development of clinical PD. Our data, therefore suggest that measuring α-synuclein tetramers in blood may have potential as a facile biomarker assay for early detection and quantitative tracking of PD progression.
Funder
Deutsches Zentrum für Neurodegenerative Erkrankungen University Bonn Maria Zambrano Fellowship Ministerio de Ciencia e Innovación ERDF Rosetrees Trust Deutsche Forschungsgemeinschaft Bundesministerium für Bildung und Forschung University of Bonn Wellcome Trust NIH UK DRI Eisei pharmaceuticals US National Institute of Neurological Disorders Chan Zuckerberg Collaborative Pairs Initiative Phase 2 UK Dementia Research Institute (DRI), which receives its funding from DRI Ltd., the UK Medical Research Council and Alzheimer’s Society, and Alzheimer’s Research UK.
Publisher
Springer Science and Business Media LLC
Reference74 articles.
1. Abdullah R, Patil KS, Rosen B, Pal R, Prabhudesai S, Lee S, Basak I, Hoedt E, Yang P, Panick K et al (2017) Subcellular Parkinson’s disease-specific alpha-synuclein species show altered behavior in neurodegeneration. Mol Neurobiol 54:7639–7655 2. Alam P, Bousset L, Melki R, Otzen DE (2019) α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem 150:522–534 3. Araki K, Yagi N, Nakatani R, Sekiguchi H, So M, Yagi H, Ohta N, Nagai Y, Goto Y, Mochizuki H (2016) A small-angle X-ray scattering study of alpha-synuclein from human red blood cells. Sci Rep 6:30473 4. Barba L, Paolini Paoletti F, Bellomo G, Gaetani L, Halbgebauer S, Oeckl P, Otto M, Parnetti L (2022) Alpha and beta synucleins: from pathophysiology to clinical application as biomarkers. Mov Disord 37:669–683 5. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P et al (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5:55–59
|
|